Improved bioavailability of darunavir by use of kappa-carrageenan versus microcrystalline cellulose as pelletisation aid.
暂无分享,去创建一个
Lieven Baert | Peter Kleinebudde | Markus Thommes | Jan Rosier | Marian Geldof | P. Kleinebudde | M. Thommes | M. Geldof | L. Baert | Gerben van 't Klooster | Laurent Schueller | G. van 't Klooster | Laurent Schueller | J. Rosier
[1] Ich Harmonised,et al. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .
[2] P. Kleinebudde. Use of a power-consumption-controlled extruder in the development of pellet formulations. , 1995, Journal of pharmaceutical sciences.
[3] Irene T. Weber,et al. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.
[4] J. Schwartz,et al. Drug release from a multiparticulate pellet system. , 1996, Pharmaceutical development and technology.
[5] P. Kleinebudde,et al. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[6] R. Haubrich,et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients , 2007, AIDS.
[7] P. Kleinebudde,et al. Influence of the Granulation Step on Pellets Prepared by Extrusion/Spheronization , 1999 .
[8] Jean Paul Remon,et al. Extrusion-spheronisation A literature review , 1995 .
[9] P. Kleinebudde,et al. Preliminary assessment of carrageenan as excipient for extrusion/spheronisation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[10] M. Youle. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. , 2007, The Journal of antimicrobial chemotherapy.
[11] P. Kleinebudde,et al. Effect of drying on extruded pellets based on κ-carrageenan , 2007 .
[12] Peter Kleinebudde,et al. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[13] P. Kleinebudde,et al. Properties of pellets manufactured by wet extrusion/spheronization process using κ-carrageenan: Effect of process parameters , 2007, AAPS PharmSciTech.
[14] Isaac Ghebre-Sellassie,et al. Pharmaceutical Pelletization Technology , 2022 .